



## GCUK Standard Prescriptions - Benign and other doses

| Diagnosis           | Site         | modality | Total Dose (Gy) | No. of fractions | Dose per fraction (Gy) | Schedule       | Max Overall Treat Time | Source of prescription  | Comment   |
|---------------------|--------------|----------|-----------------|------------------|------------------------|----------------|------------------------|---|---|
|                     |              |          |                 |                  |                        |                |                        |   |   |
| Gynecomastia        | Breast buds  |          | 8-10            | 1                | 8-10                   | single         |                        | Mount Vernon NHS  |   |
|                     | Breast buds  | electron | 21              | 3                | 7                      | alternate days |                        | Mount Vernon NHS  |   |
|                     | Breast buds  |          | 15              | 3                | 5                      | daily          | 3                      | Nottingham NHS  |   |
| Pleomorphic Adenoma | Parotid      | x-ray    | 50              | 25               | 2                      | daily          |                        | CRT (GU1-1), <i>Practical Radiotherapy Planning 4th edition</i> | Recommended for Recurrent Pleomorphic Adenoma<br>Royal Surrey Protocol (pg35): 45Gy/20# if small volume < 42cm <sup>2</sup> field size    |
|                     | Parotid      | x-ray    | 45              | 25               | 2                      | daily          |                        | RCR   |   |
| Thyroid eye disease | Eye          | x-ray    | 20              | 10               | 2                      | Daily          | 2 weeks                | QE Birmingham NHS   | QE Birmingham NHS Ocular Protocol "Thyroid Exophthalmos"  |
| Dupuytren's         | Dupuytren's  | electron | 15              | 5                | 3                      | daily          | 2 weeks                | GenesisCare Dupuytren's and Ledderhose Protocol                 | 1st 15 Gy given. After a 6-8 week gap the dose regime is repeated. 6-12 weeks is acceptable in some instances (CRT WD6-67)                |
|                     | Dupuytren's  | electron | 21              | 7                | 3                      | alternate days | 2.5 weeks              | GenesisCare Dupuytren's and Ledderhose Protocol                 |   |
|                     | Re-treatment | electron | 15              | 5                | 3                      | daily          | 1 week                 | GenesisCare Dupuytren's and Ledderhose Protocol                 | Single phase only   |
|                     | Ledderhose   | electron | 15              | 5                | 3                      | daily          |                        | GenesisCare Dupuytren's and Ledderhose Protocol                 | 1st 15 Gy given. After a 6-8 week gap the dose regime is repeated. 6-12 weeks is acceptable in some instances (Dr Shaffer/AJP March 2017) |

|                     |                     |          |       |    |         |                      |           |  |   |
|---------------------|---------------------|----------|-------|----|---------|----------------------|-----------|--|---|
| Ledderhose          | Ledderhose          | electron | 21    | 7  | 3       | alternate days       | 2.5 weeks | GenesisCare Dupuytren's and Ledderhose Protocol                        |   |
|                     | Re-treatment        | electron | 15    | 5  | 3       | daily                | 1 week    | GenesisCare Dupuytren's and Ledderhose Protocol                        | Single phase only   |
| Keloid scars        | various             | electron | 8     | 1  | 8       | single               |           | CRT SO16-44  |   |
|                     | various             | electron | 9     | 1  | 9       | single               |           | Portsmouth NHS (2012)  | 24-72 hours after surgery                                       |
|                     | various             | electron | 10    | 1  | 10      | single               |           | GenesisCare Keloid protocol  | irradiation within 24hours of operation                         |
|                     | various             | electron | 15    | 3  | 5       | Daily                |           | GenesisCare Keloid protocol  | High recurrence risk  |
|                     | various             | electron | 18    | 3  | 6       | daily                |           | GenesisCare Keloid protocol  | High recurrence risk - anterior chest wall, scapula, suprapubic |
|                     | various             | electron | 20    | 4  | 5       | daily                |           | GenesisCare Keloid protocol  | High recurrence risk - anterior chest wall, scapula, suprapubic |
|                     | various             | electron | 15    | 2  | 7.5     | daily                |           | GenesisCare Keloid protocol  | High recurrence risk  |
|                     | earlobe             | electron | 10    | 2  | 5       | daily                |           | GenesisCare Keloid protocol  |   |
| Plantar Fasciitis   | Plantar Fasciitis   | x-ray    | 6     | 6  | 1       | 2 fractions per week | 3 weeks   | GenesisCare Plantar Fasciitis and achilles tendonitis Protocol         |   |
| Achilles Tendonitis | Achilles Tendonitis | x-ray    | 6     | 6  | 1       | 2 fractions per week | 3 weeks   | GenesisCare Plantar Fasciitis and Achilles tendonitis Protocol         |   |
|                     | Torso and Head      | x-ray    | 45-50 | 25 | 1.8-2   | daily                | 5 weeks   | UK SPOT Protocol: VMAT treatment for Extended skin field cancerisation |   |
|                     | Torso and Head SIB  | x-ray    | 55-60 | 25 | 2.2-2.4 | daily                | 5 weeks   | UK SPOT Protocol: VMAT treatment for Extended skin field cancerisation | SIB dose to be used alongside 45-50Gy / 25#                     |

|                          |                         |       |       |       |         |        |         |  |  |
|--------------------------|-------------------------|-------|-------|-------|---------|--------|---------|--|--|
| SPOT                     | Whole nose              | x-ray | 60    | 30    | 2       | daily  | 6 weeks | UK SPOT Protocol: VMAT treatment for Extended skin field cancerisation |  |
|                          | Whole nose              | x-ray | 45    | 25    | 1.8     | daily  | 5 weeks | UK SPOT Protocol: VMAT treatment for Extended skin field cancerisation | with a 55Gy / 25# boost  |
|                          | Sub-total nose or scalp | x-ray | 50-55 | 20-25 | 2.2-2.5 | daily  | 5 weeks | UK SPOT Protocol: VMAT treatment for Extended skin field cancerisation |  |
|                          | Limbs                   | x-ray | 45    | 25    | 1.8     | daily  | 7 weeks | UK SPOT Protocol: VMAT treatment for Extended skin field cancerisation | Mandatory break of at least 2 weeks after 10 fractions                                   |
|                          | Limb SIB                | x-ray | 55-60 | 25    | 2.2-2.4 | daily  | 7 weeks | UK SPOT Protocol: VMAT treatment for Extended skin field cancerisation |  |
| Heterotopic Ossification | Bone                    | x-ray | 7     | 1     | 7       | single |         | See reference; KS approved   | Pre or post-operative dose. Radiation treatment must occur within 4-72 hours pre/post op |